These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32493746)

  • 1. Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics.
    Buss CG; Bhatia SN
    Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13428-13436. PubMed ID: 32493746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
    Reilley MJ; Morrow B; Ager CR; Liu A; Hong DS; Curran MA
    J Immunother Cancer; 2019 Nov; 7(1):323. PubMed ID: 31771649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery routes matter: Safety and efficacy of intratumoral immunotherapy.
    De Lombaerde E; De Wever O; De Geest BG
    Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188526. PubMed ID: 33617921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer Immunotherapy through Reversion of Tumor-Associated Macrophages.
    Zhang Y; Wu L; Li Z; Zhang W; Luo F; Chu Y; Chen G
    Biomacromolecules; 2018 Jun; 19(6):2098-2108. PubMed ID: 29634251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Clinical Approaches and Emerging Evidence on Immune-Checkpoint Inhibitors as Anti-Cancer Therapeutics: CTLA-4 and PD-1 Pathways and Beyond.
    Christodoulou MI; Zaravinos A
    Crit Rev Immunol; 2019; 39(5):379-408. PubMed ID: 32422018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation.
    Mottas I; Bekdemir A; Cereghetti A; Spagnuolo L; Yang YS; Müller M; Irvine DJ; Stellacci F; Bourquin C
    Biomaterials; 2019 Jan; 190-191():111-120. PubMed ID: 30415018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
    Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
    J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
    Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
    J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The application of nanotechnology in immune checkpoint blockade for cancer treatment.
    Deng H; Zhang Z
    J Control Release; 2018 Nov; 290():28-45. PubMed ID: 30287266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.
    Kortylewski M; Moreira D
    Cancer Immunol Immunother; 2017 Aug; 66(8):979-988. PubMed ID: 28214929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.
    van Hooren L; Sandin LC; Moskalev I; Ellmark P; Dimberg A; Black P; Tötterman TH; Mangsbo SM
    Eur J Immunol; 2017 Feb; 47(2):385-393. PubMed ID: 27873300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
    Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
    J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy.
    Chen Q; Chen J; Yang Z; Xu J; Xu L; Liang C; Han X; Liu Z
    Adv Mater; 2019 Mar; 31(10):e1802228. PubMed ID: 30663118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
    Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L
    J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymeric nanoparticle gel for intracellular mRNA delivery and immunological reprogramming of tumors.
    Neshat SY; Chan CHR; Harris J; Zmily OM; Est-Witte S; Karlsson J; Shannon SR; Jain M; Doloff JC; Green JJ; Tzeng SY
    Biomaterials; 2023 Sep; 300():122185. PubMed ID: 37290232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.